Full-Time

Executive Director

Pipeline Project Leadership

Confirmed live in the last 24 hours

Legend Biotech

Legend Biotech

1,001-5,000 employees

Develops and commercializes cell therapies

No salary listed

Expert

Somerset County, NJ, USA

This is a hybrid position, which may require some in-office days.

Category
Public Health
Biology Lab & Research
Biology & Biotech
Required Skills
Agile
Risk Management
Requirements
  • Advanced degree (MD, PhD, PharmD) or equivalent with 15 years of industry experience and demonstrated leadership in a project management and/or supervisory role
  • 15+ years of industry experience in a biotech or pharmaceutical setting
  • Excellent leadership, emotional intelligence, and communication skills
  • Experience with development of autologous or allogeneic cell therapies and viral vectors, and the overall pharmaceutical development process and road maps
  • Experience in therapeutic areas such as hematological malignancies, autoimmune diseases, and solid tumors
  • Strong grasp of science with analytical skills to drive data-based decision making
  • Demonstrated proficiency in drug development with sufficient awareness of CMC challenges for cell therapies and viral vectors
  • Robust understanding of regulatory consideration of product development
  • Proven track record of leading cross-functional teams, solving complex problems, prioritization, and building teams
  • Creative, strategic thinking
  • Composure during challenging times
  • Strong troubleshooting skills
  • Language: English. Mandarin is a plus.
Responsibilities
  • Establish and lead cross-functional project teams for each endorsed project
  • Lead cross-functional teams in harnessing the strengths of functional area leaders, establish a cohesive integrated development strategy, set clear team goals, and foster a collaborative team dynamic
  • Implement effective project leadership and project management methodologies to ensure the timely and successful delivery of results.
  • Identify relevant cross functional dependencies and constraints and work to facilitate timely resolution to achieve the desired outcomes.
  • Enable effective and rapid decision making with clear risks, mitigations, go/no-go criteria as part of a holistic operational plan to achieve success
  • Operates with strong financials, company priorities and needs of partners
  • Lead teams in preparation and execution of comprehensive development plans (e.g product, clinical, regulatory, commercial) and associated documents for each development program ensuring the requirements for all relevant areas are achieved
  • Mentor and develop future talent from technical functions and create a pipeline for project leaders for early-stage programs
  • In collaboration with the project manager, lead the creation and adjustment of aggressive timeline strategies with clear communication of underlying assumptions
  • In collaboration with the project manager, proactively monitor project goals and provide timely communication on progress across all relevant levels of the organization including senior leadership
  • Function as a single point of accountability for each project, including those with junior project leaders mentored by the successful candidate
  • Adjust project strategies to changing company priorities and portfolio evolution
  • In collaboration with the project manager, ensure high quality project execution
  • Direct the advancement of each project through governance endorsement at each stage-gate review
  • In collaboration with the project manager, ensure a robust risk register and execution of mitigation strategies
  • Maintain strong awareness of competitive landscape and adapt project approaches to maintain best/first in class
  • Collaborate with the project management office to evolve company processes for product development
  • Establish a collaborative, science-based, agile, innovative, continuous improvement, and patient-focused culture for each project team
  • Contribute to portfolio vision and prioritization
  • Function as a single point of accountability for each project, including those with junior project leaders mentored by the successful candidate
  • Build strong collaborative relationships with functional areas and creates a culture of transparency, unity and engagement
  • Resolve conflict and proactively identify performance issues detrimental to the team and organization

Legend Biotech develops and commercializes cell therapies aimed at treating serious diseases, particularly cancers like hematological malignancies and solid tumors. Their approach is technology agnostic, allowing them to explore various methods to find effective treatments. The company operates within the personalized medicine sector, focusing on discovering, developing, and bringing new therapies to market. They generate revenue through licensing and selling their therapies, including CAR-T therapies, which involve modifying a patient's cells to combat cancer. Legend Biotech emphasizes transparency with investors, regularly updating them on financial results and business developments.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Franklin Township, New Jersey

Founded

2014

Simplify Jobs

Simplify's Take

What believers are saying

  • Collaboration with Multiply Labs could enhance manufacturing efficiency through automation.
  • European Commission's approval of CARVYKTI® expands market reach in multiple myeloma treatment.
  • New R&D facility in Philadelphia may lead to breakthroughs in next-generation cell therapies.

What critics are saying

  • Competition from Amgen's Imdelltra may impact market share in oncology.
  • Expansion into Philadelphia R&D facility could strain financial resources if mismanaged.
  • Dependency on MaxCyte's technology poses risks if MaxCyte faces operational issues.

What makes Legend Biotech unique

  • Legend Biotech focuses on novel cell therapies for oncology, including CAR-T and NK cells.
  • The company is technology agnostic, exploring multiple platforms for effective treatments.
  • Legend Biotech's business model includes discovery, development, and commercialization of therapies.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

Paid Sick Leave

Paid Holidays

Remote Work Options

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
The Yellow Brick Road
Mar 3rd, 2025
YB new stock pitches (Mon, Mar 3)

Legend Biotech Corporation (LEGN) is developing a promising CAR-T cancer drug in partnership with Johnson & Johnson.

ROI-NJ
Nov 5th, 2024
Legend Biotech Names Alan Bash As Leader Of Its Cer-T Product

Legend Biotech Corporation on Tuesday said it appointed Alan Bash as president of its CAR-T product CARVYKTI®. In this newly created role, Bash will be responsible for managing the continued growth of CARVYKTI®, overseeing the Somerset-based firm’s commercial, technical operations, and quality functions of the franchise.“This expansion in our leadership structure is on the heels of CARVYKTI’s recent successes, including recent approvals from the U.S. Food and Drug Administration and European Commission for label expansion,” Ying Huang, chief executive officer of Legend Biotech said. “Legend Biotech welcomes Alan and is confident that his wealth of operational knowledge in oncology will help further strengthen the Company’s leadership role in the treatment of multiple myeloma.”Previously, Bash served as chief executive officer for two oncology-focused biotech companies, most recently at ZielBio, and before that, as president and CEO at Checkmate Pharmaceuticals. He also had a 23-year career with Bristol Myers Squibb, where he held various leadership positions across all major therapeutic areas—including oncology—driving the U.S. launch of Opdivo® and the expansion of additional cancer treatments such as Yervoy® and Erbitux ®.Bash contributed to several blockbuster products in collaboration with other companies, including Abilify® with Otsuka and Eliquis® with Pfizer.“As the fastest launched CAR-T product on the market, CARVYKTI has already produced impressive momentum,” Bash said

GlobeNewswire
Nov 4th, 2024
Legend Biotech Appoints Alan Bash As President Of Carvykti(R)

SOMERSET, N.J., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today announced the appointment of Alan Bash as the Company’s President of CARVYKTI®. In this newly created role, Mr. Bash will be responsible for managing the continued growth of CARVYKTI®, overseeing Legend Biotech’s commercial, technical operations, and quality functions of the franchise.“This expansion in our leadership structure is on the heels of CARVYKTI’s recent successes, including recent approvals from the U.S. Food and Drug Administration and European Commission for label expansion,” said Ying Huang, Ph.D., Chief Executive Officer of Legend Biotech. “Legend Biotech welcomes Alan and is confident that his wealth of operational knowledge in oncology will help further strengthen the Company’s leadership role in the treatment of multiple myeloma.”Mr

BioBuzz
Oct 30th, 2024
Legend Biotech Chooses Philadelphia for New R&D Center

With a global workforce of 1,500 employees, including 350 in R&D, Legend is expanding its manufacturing capabilities with new facilities in New Jersey and beyond.

Global Culture Review
Oct 3rd, 2024
Legend Biotech to Establish New, State-of-the-Art Cell Therapy Research and Development Facility in Philadelphia

SOMERSET, N.J., Oct. 03, 2024 (GLOBE NEWSWIRE) - Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), announced it is establishing a new, state-of-the-art research and development (R&D) facility in Philadelphia, Pennsylvania, to advance its portfolio of next-generation cell therapies.